Business Context and Reporting Period
This Form 8-K was filed by Indivior PLC on June 2, 2025, reporting events occurring on the same date. The registrant is a pharmaceutical company incorporated in England and Wales with principal executive offices in North Chesterfield, Virginia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- London Delisting: The Company announced its intention to cancel its secondary listing on the London Stock Exchange (LSE).
- Regulatory Action: Indivior has requested the U.K. Financial Conduct Authority (FCA) to cancel the listing of its Ordinary Shares on the Official List and admit them to trading on the LSE main market.
- Effective Dates: The delisting is expected to become effective at 8:00 a.m. U.K. time on July 25, 2025, with the last trading day on the LSE being July 24, 2025.
- Nasdaq Status: The London Delisting has no impact on the Company's primary listing on The Nasdaq Stock Market LLC, where it will continue to trade under the symbol INDV.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the operational change of delisting from the LSE. The primary contingency noted is the regulatory approval process with the FCA to finalize the cancellation of the listing.
Investor Verification Checklist
- Confirm the final effective date of the LSE delisting (expected July 25, 2025).
- Verify that trading continues uninterrupted on Nasdaq under the symbol INDV.
- Review the press release (Exhibit 99.1) for any additional details regarding the rationale for the delisting not included in the 8-K summary.
- Monitor for any shareholder communications regarding the transition of the secondary listing.